(And those Wegovy ads so irritating
Menstrual irregularities are not listed as a recognised adverse reaction in the Summary of Product Characteristics (SmPC) approved by the Medicines and Healthcare products Regulatory Agency (MHRA), though some women have reported changes to their menstrual cycle while taking this medication
Preclinical research indicates that intra-articular (IA) liraglutide attenuates synovial inflammation, decreases catabolic markers such as ADAMTS-5, and limits cartilage and bone damage across three experimental OA models, including MIA (mono-iodo-acetate), DMM (destabilization of the medial meniscus), and collagenase II-induced OA
These can include high blood pressure, type 2 diabetes, or high cholesterol, for example
That finding is particularly relevant for anyone using peptides for fat loss or GLP-1 medications for weight management